Table 1 Baseline characteristics, types of β-lactams, and severity of patients with neutropenic pneumonia
Variables | β-lactam group (n = 72) | Combination group (n = 93) | P-value |
|---|---|---|---|
Demographic data | |||
Age, years | 61 ± 11 | 62 ± 10 | 0.296 |
Male sex | 59 (81.9%) | 59 (63.4%) | 0.009 |
Smoking history | 29 (40.3%) | 27 (29.0%) | 0.130 |
Comorbid conditions | |||
Hypertension | 14 (19.4%) | 28 (30.1%) | 0.119 |
Diabetes mellitus | 5 (6.9%) | 12 (12.9%) | 0.212 |
Cardiovascular diseases | 5 (6.9%) | 2 (2.2%) | 0.130 |
Chronic lung diseases | 3 (4.2%) | 6 (6.5%) | 0.733 |
Chronic liver diseases | 3 (4.2%) | 3 (3.2%) | 1.000 |
Chronic renal diseases | 0 (0.0%) | 6 (6.5%) | 0.036 |
Types of β-lactams | |||
Cefepime | 40 (55.6%) | 64 (68.8%) | 0.080 |
Ceftazidimea | 20 (27.8%) | 2 (2.2%) | < 0.001 |
Piperacillin/tazobactam | 6 (8.3%) | 21 (22.6%) | 0.014 |
Carbapenem | 6 (8.3%) | 6 (6.5%) | 0.644 |
Duration of antibiotic administration, days | 12.4 (8.9–16.2) | 11.7 (9.1–14.4) | 0.646 |
Severity variables | |||
Presence of bacteremia | 16 (22.0%) | 12 (12.9%) | 0.114 |
Duration of neutropenia, days | 1.5 (0.9–3.1) | 1.4 (1.0–2.9) | 0.773 |
CRP, mg/dL | 15.9 (6.5–24.0) | 17.0 (6.4–25.9) | 0.669 |
CURB-65 | 1 (0–2) | 1 (0–2) | 0.898 |
MASCC risk index | 16 (13–18) | 16 (16–21) | 0.059 |